Testing a new treatment to prevent cholera outbreaks using bacteriophages.
Preparation of a Phase I/II safety and efficacy trial for a cholera phage cocktail intervention
This study is testing a new treatment using special viruses that can help protect communities at risk of cholera, aiming to quickly reduce the spread of this serious illness.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Phagepro, INC. NIH-funded |
| Lab location | 1 site (Mansfield, UNITED STATES) |
| Project ID | NIH-10838235 on NIH RePORTER |
What this research studies
This research focuses on developing a new intervention to prevent cholera, a severe diarrheal disease caused by the bacterium Vibrio cholerae. The approach involves using a bacteriophage cocktail, which is a type of virus that specifically targets and kills bacteria, to provide rapid protection against cholera in communities at risk. The study will assess the safety and effectiveness of this treatment in a clinical trial setting, aiming to offer a fast-acting solution to curb the spread of cholera, especially in areas with high transmission rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults living in cholera-endemic regions, particularly those who may have been exposed to cholera or are at high risk of infection.
Not a fit: Patients who are not at risk of cholera or those who have already been vaccinated against cholera may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective method to prevent cholera outbreaks, potentially saving lives and reducing the burden of this disease.
How similar studies have performed: While the use of bacteriophages for treating bacterial infections is a growing field, this specific approach for cholera prevention is novel and has not been extensively tested in clinical settings.
Where this research is happening
Mansfield, UNITED STATES
- Phagepro, INC. — Mansfield, United States (Active)
Researchers
- Principal investigator: Yen, Minmin — Phagepro, INC.
- Study coordinator: Yen, Minmin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.